Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 admiral trial Meeting Abstract

  


Authors: Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; Fabbiano, F.; Di Stasi, A.; Stuart, R.; Olin, R.; Kasner, M.; Ciceri, F.; Chou, W.; Podoltsev, N.; Recher, C.; Yokoyama, H.; Hosono, N.; Yoon, S.; Pardee, J. L. T.; Fathi, A. T.; Liu, C.; Liu, X.; Bahceci, E.; Levis, M. J.
Abstract Title: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 admiral trial
Meeting Title: 47th Congress of the Italian Society of Haematology
Journal Title: Haematologica
Volume: 104
Issue: Suppl. 2
Meeting Dates: 2019 Oct 7-9
Meeting Location: Rome, Italy
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2019-10-01
Start Page: 2
Language: English
ACCESSION: WOS:000493893200004
PROVIDER: wos
Notes: Meeting Abstract: B003 -- Source: Wos